KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Equity Ratio (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 8 years of Equity Ratio data on record, last reported at 0.03 in Q4 2024.

  • For Q4 2024, Equity Ratio fell 642.75% year-over-year to 0.03; the TTM value through Dec 2024 reached 0.03, down 642.75%, while the annual FY2024 figure was 0.03, 642.75% down from the prior year.
  • Equity Ratio reached 0.03 in Q4 2024 per AMRX's latest filing, down from 0.03 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.1 in Q3 2021 and bottomed at 0.03 in Q4 2024.
  • Average Equity Ratio over 5 years is 0.04, with a median of 0.05 recorded in 2022.
  • Peak YoY movement for Equity Ratio: grew 8.18% in 2021, then plummeted 642.75% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.09 in 2020, then rose by 8.18% to 0.09 in 2021, then crashed by 48.01% to 0.05 in 2022, then crashed by 88.1% to 0.01 in 2023, then tumbled by 642.75% to 0.03 in 2024.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.03 in Q4 2024, 0.03 in Q3 2024, and 0.02 in Q2 2024.